GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Harvard Apparatus Regenerative Technology Inc (OTCPK:HRGN) » Definitions » Capex-to-Operating-Cash-Flow

Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Harvard Apparatus Regenerative Technology Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Harvard Apparatus Regenerative Technology's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-1.22 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Harvard Apparatus Regenerative Technology Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Harvard Apparatus Regenerative Technology Capex-to-Operating-Cash-Flow Chart

Harvard Apparatus Regenerative Technology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Harvard Apparatus Regenerative Technology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow falls into.



Harvard Apparatus Regenerative Technology Capex-to-Operating-Cash-Flow Calculation

Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.011) / -6.939
=N/A

Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.218
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Harvard Apparatus Regenerative Technology  (OTCPK:HRGN) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Harvard Apparatus Regenerative Technology Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Harvard Apparatus Regenerative Technology's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Harvard Apparatus Regenerative Technology (Harvard Apparatus Regenerative Technology) Business Description

Traded in Other Exchanges
N/A
Address
84 October Hill Road, Suite 11, Holliston, MA, USA, 01746
Harvard Apparatus Regenerative Technology Inc is a clinical-stage biotechnology company developing regenerative-medicine treatments for disorders of the gastrointestinal system and the airway resulting from cancer, trauma, or birth defects. The company's technology is based on its proprietary cell-therapy platform that uses a patient's own stem cells to regenerate and restore function to damaged organs.
Executives
Junli He director C/O NO.1, COUNTRY GARDEN ROAD, BEIJIAO TOWN, SHUNDE DISTRICT, FOSHAN F4 528300
James E. Shmerling director 975 JOHNSON FERRY ROAD, SUITE 450, ATLANTA GA 30342
Dst Capital Llc 10 percent owner C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ronald J Packard director 2300 CORPORATE PARK DRIVE, HERNDON VA 20171
Jing Chen director C/O BIOSTAGE,INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 02110
Hong Yu officer: President C/O BIOSTAGE, INC. 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Damasio Joseph Luis Jr officer: Chief Financial Officer 14 NORFOLK AVENUE, SOUTH EASTON MA 02375
David Green director, officer: See Remarks C/O HARVARD BIOSCIENCE INC, 84 OCTOBER HILL ROAD, HOLLISTON MA 01746-1371
William Fodor officer: Chief Scientific Officer C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Peter A. Pellegrino officer: Interim VP of Finance C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Herman Sanchez director 84 OCTOBER HILL ROAD, SUITE 11, HOLLISTON MA 01746
James Mastridge officer: See Remarks C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746
Jeffrey E Young director 60 WESTVIEW STREET, LEXINGTON MA 02421
Wei Zhang director C/O BIOSTAGE, INC., 84 OCTOBER HILL ROAD, HOLLISTON MA 01746
Ting Li director C/O BIOSTAGE, INC., 84 OCTOBER HILL RD., HOLLISTON MA 01746